Shanghai MicroPort EP Medtech Co Ltd is engaged in the research and development, production and sales of various medical devices and equipment related to cardiac electrophysiology interventional diagnosis and treatment.
2010
n/a
LTM Revenue $62.2M
LTM EBITDA $11.0M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MicroPort EP has a last 12-month revenue of $62.2M and a last 12-month EBITDA of $11.0M.
In the most recent fiscal year, MicroPort EP achieved revenue of $56.9M and an EBITDA of $12.5M.
MicroPort EP expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MicroPort EP valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $45.4M | $56.9M | XXX | XXX | XXX |
Gross Profit | $24.8M | $28.8M | XXX | XXX | XXX |
Gross Margin | 55% | 51% | XXX | XXX | XXX |
EBITDA | $4.9M | $12.5M | XXX | XXX | XXX |
EBITDA Margin | 11% | 22% | XXX | XXX | XXX |
Net Profit | $0.4M | $0.8M | XXX | XXX | XXX |
Net Margin | 1% | 1% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, MicroPort EP's stock price is CNY 22 (or $3).
MicroPort EP has current market cap of CNY 10.2B (or $1.4B), and EV of CNY 8.8B (or $1.2B).
See MicroPort EP trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.2B | $1.4B | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, MicroPort EP has market cap of $1.4B and EV of $1.2B.
MicroPort EP's trades at 19.6x LTM EV/Revenue multiple, and 110.7x LTM EBITDA.
Analysts estimate MicroPort EP's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for MicroPort EP and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.2B | XXX | XXX | XXX |
EV/Revenue | 21.4x | XXX | XXX | XXX |
EV/EBITDA | 97.7x | XXX | XXX | XXX |
P/E | 195.3x | XXX | XXX | XXX |
P/E/Growth | 4.8x | XXX | XXX | XXX |
EV/FCF | 375.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMicroPort EP's NTM/LTM revenue growth is 30%
MicroPort EP's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, MicroPort EP's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate MicroPort EP's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for MicroPort EP and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 26% | XXX | XXX | XXX | XXX |
EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
EBITDA Growth | 153% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 51% | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | n/a | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
Opex to Revenue | 50% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MicroPort EP acquired XXX companies to date.
Last acquisition by MicroPort EP was XXXXXXXX, XXXXX XXXXX XXXXXX . MicroPort EP acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was MicroPort EP founded? | MicroPort EP was founded in 2010. |
Where is MicroPort EP headquartered? | MicroPort EP is headquartered in China. |
Is MicroPort EP publicy listed? | Yes, MicroPort EP is a public company listed on SHG. |
What is the stock symbol of MicroPort EP? | MicroPort EP trades under 688351 ticker. |
When did MicroPort EP go public? | MicroPort EP went public in 2022. |
Who are competitors of MicroPort EP? | Similar companies to MicroPort EP include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
What is the current market cap of MicroPort EP? | MicroPort EP's current market cap is $1.4B |
What is the current revenue of MicroPort EP? | MicroPort EP's last 12-month revenue is $62.2M. |
What is the current EBITDA of MicroPort EP? | MicroPort EP's last 12-month EBITDA is $11.0M. |
What is the current EV/Revenue multiple of MicroPort EP? | Current revenue multiple of MicroPort EP is 19.6x. |
What is the current EV/EBITDA multiple of MicroPort EP? | Current EBITDA multiple of MicroPort EP is 110.7x. |
What is the current revenue growth of MicroPort EP? | MicroPort EP revenue growth between 2023 and 2024 was 26%. |
Is MicroPort EP profitable? | Yes, MicroPort EP is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.